Back to search results

Comparing Simbrinza and Rocklatan to Cosopt and Latanoprost for Open Angle Glaucoma

This study is comparing two common eye drop combinations, Simbrinza and Rocklatan, against another combination you might already be using, Cosopt and Latanoprost. The goal is to see which combination is most effective at lowering eye pressure (intraocular pressure or IOP) in people with mild to moderate open-angle glaucoma (OAG). You may be able to join if you are an adult, 18 years or older, with mild to moderate OAG and have been using Cosopt and Latanoprost eye drops for at least one month. The study will measure the decrease in your eye pressure after 8 weeks to determine which treatment works best. The current status of this study is unclear.

Study design
This is a randomized, multi-site study involving approximately 70 adult participants. Participants will be assigned to one of the treatment groups by chance.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary outcome is measured at week 8, indicating follow-up for at least that duration.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06883123

Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost

Recruiting
PHASE4Ages 18+InterventionalBasic science
Prairie Eye Center
~70 participants
Updated 2025-05-15 on ClinicalTrials.gov
What's tested:Simbrinza 0.2%-1% Ophthalmic SuspensionRocklatan 0.02%-0.005% Ophthalmic SolutionCosopt PF 2%-0.5% Ophthalmic SolutionLatanoprost 0.005% Ophthalmic Solution

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Decrease in mean diurnal IOP
Measured over from baseline at week 8

Conditions

Open Angle Glaucoma

Explore related trials

Open Angle Glaucoma

Where it's being run

1 sites across 1 states
Illinois1

Study leadership

  • Sandra Yeh, MD · PRINCIPAL_INVESTIGATOR · Prairie Eye Center

Who to contact

Jennifer Lyons
[email protected]
217-257-3102
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adults aged Eighteen (18) years and older with a diagnosis of mild to moderate open-angle glaucoma (OAG), currently on an on-label use of combination topical medication of Cosopt and Latanoprost for a minimum of 1 month. Evidence of optic nerve damage will be based on AAO Preferred Practice Patterns guidelines using either or both of the following:
Optic disc or retinal nerve fiber layer (RNFL) structural abnormalities
Diffuse or focal narrowing, or notching, of the optic disc rim, especially at the inferior or superior poles, which forms the basis for the ISNT rule
Progressive narrowing of the neuroretinal rim with an associated increase in cupping of the optic disc
Diffuse or localized abnormalities of the parapapillary RNFL, especially at the inferior or superior poles
Disc rim, parapapillary RNFL, or lamina cribrosa hemorrhages
Optic disc neural rim asymmetry of the two eyes consistent with loss of neural tissue
Large extent of parapapillary atrophy
Reliable and reproducible visual field abnormality considered a valid representation of the subject's functional status
Visual field damage consistent with RNFL damage (e.g. nasal step, arcuate field defect, or paracentral depression in clusters of test sites)
Visual field loss across the horizontal midline in one hemifield that exceeds loss in the opposite hemifield (in early/ moderate cases)
Absence of other known explanations (e.g. optic disc drusen, optic nerve pit)
Mean diurnal IOP ≥ 18 mmHg and \< 28 mmHg at baseline in at least one eye with an inter-eye IOP difference \< 5 mmHg.
A central corneal thickness (CCT) within the range of 450-650 µm

Exclusion

Patients with prior ocular procedures or intraocular surgery within 1 year prior to baseline (e.g. cataract surgery).
Patients with prior history of glaucoma surgeries or laser treatment except patients with history of SLT \>1 yr prior to baseline.
Contraindications or known hypersensitivity to any or all the study medications including Rocklatan, Simbrinza, Cosopt and Latanoprost or related class of drugs.
Patients with known history or presence of uncontrolled systemic diseases including diseases that, in investigator's opinion, may make it unsafe or undesirable for the subject to participate in the study and/ or limit adherence.
Patients with known history or presence of significant ocular diseases including corneal diseases, dystrophies or abnormalities that would prevent accurate IOP readings with GAT.
Patients with a history of uncontrolled IOP with the combination of either Rocklatan + Simbrinza or Cosopt + Latanoprost dual therapy.
Significant ocular surface findings (e.g. hyperemia, irritation) found during slit lamp examination that might affect the study.
Chronic use of any systemic medication for chronic diseases that may affect IOP.
Subjects who are pregnant, lactating or planning a pregnancy.
Any condition in the opinion in the investigator that would potentially confound the results of this study

What this trial measures

  • Decrease in mean diurnal IOPfrom baseline at week 8

    Mean diurnal IOP is determined as the average IOP measured at 8:30am, 12:00pm and 3:30pm